Achondroplasia follows an autosomal dominant inheritance pattern, meaning a single copy of the mutated gene is enough to cause the condition. About 1 in 22,000 babies worldwide are born with achondroplasia, and roughly 80% of cases arise from a brand-new (de novo) mutation in families with no prior history.
The Gene Behind Achondroplasia
Nearly all cases trace back to a single, specific change in the FGFR3 gene on chromosome 4. This gene encodes a receptor protein that normally helps regulate how cartilage cells in growth plates multiply and mature into bone. The mutation swaps one amino acid for another at position 380 of the protein, and this tiny change causes the receptor to become overactive.
An overactive FGFR3 receptor does the opposite of what you might expect. Instead of accelerating growth, it slams the brakes on it. The amped-up signaling suppresses the proliferation and maturation of cartilage cells in growth plates, which are the zones near the ends of long bones where new bone forms during childhood. The result is shorter limbs, particularly the upper arms and thighs, along with characteristic changes in the skull and spine. This same mutation appears in virtually every confirmed case across all ethnic populations studied.
What “Autosomal Dominant” Means in Practice
Humans carry two copies of every gene, one from each parent. With an autosomal dominant condition, inheriting just one altered copy is enough. The gene sits on chromosome 4, which is not a sex chromosome, so the condition affects boys and girls equally.
If one parent has achondroplasia and the other is average-statured, each pregnancy carries a 50% chance the child will have achondroplasia and a 50% chance the child will be average-statured. There is no “carrier” state where someone silently passes the gene along without being affected themselves. You either have the mutation and show the condition, or you don’t have it.
When Both Parents Have Achondroplasia
When two people with achondroplasia have children together, the math shifts. Each pregnancy has a 25% chance of producing a child with average stature, a 50% chance of achondroplasia (one mutated copy), and a 25% chance the child inherits two mutated copies, one from each parent. This double-dose form, called homozygous achondroplasia, is a severe, life-limiting condition. Affected infants typically have extreme skeletal abnormalities and a very small ribcage that compromises breathing, and most do not survive infancy.
Most Cases Are Spontaneous
The majority of children born with achondroplasia have two average-statured parents with no family history of the condition. In these cases, the FGFR3 mutation occurs spontaneously in a single sperm or egg cell before conception. This is not caused by anything either parent did or didn’t do during pregnancy.
Achondroplasia was actually the first genetic condition linked to advanced paternal age. The FGFR3 mutation arises more often in sperm than in eggs, and the frequency of the mutation increases by roughly 3% with each additional year of the father’s age. Men between 50 and 54 have about a 12-fold increased chance of having a child with achondroplasia compared to younger fathers. The reason likely involves the way sperm-producing cells continuously divide throughout a man’s life, accumulating copying errors over time.
Recurrence Risk for Average-Statured Parents
If two average-statured parents have one child with achondroplasia, they often want to know the odds for future pregnancies. In most cases the mutation was a one-time event and the chance of recurrence is extremely low. Data from Canadian genetics centers estimated a recurrence risk of about 0.02%, or roughly 1 in 443.
That small but nonzero risk exists because of a phenomenon called germline mosaicism. In rare instances, one parent carries the FGFR3 mutation in a fraction of their sperm or egg cells but not in the rest of their body. Standard genetic testing of the parent’s blood would come back normal, yet a subset of their reproductive cells carry the mutation. This is uncommon, but it explains why recurrence risk isn’t quite zero.
Prenatal Detection
Achondroplasia is typically first suspected on a third-trimester ultrasound, when shortened limb bones become more apparent. Earlier in pregnancy, the skeletal differences are too subtle to detect on imaging alone. If ultrasound findings raise concern, molecular genetic testing can confirm the diagnosis by looking directly for the FGFR3 mutation.
Traditionally, confirmatory testing required an invasive procedure to obtain fetal DNA. Newer approaches can detect the FGFR3 mutation using fragments of fetal DNA that circulate naturally in the mother’s bloodstream. This noninvasive method is particularly useful when one parent is already known to have achondroplasia, since the 50% probability per pregnancy makes early, low-risk testing especially relevant for family planning.
Key Numbers at a Glance
- Global birth prevalence: approximately 1 in 22,000 live births
- One affected parent, one unaffected: 50% chance per pregnancy
- Both parents affected: 25% average stature, 50% achondroplasia, 25% homozygous (life-limiting)
- Recurrence in unaffected parents after one affected child: roughly 0.02%
- Paternal age effect: about 3% increase in mutation frequency per additional year of the father’s age